What is Rituximab?

Rituximab (Rituximab) is a monoclonal anti-CD20 antibody indicated for the treatment of non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA), pemphigus vulgaris (PV), and rheumatoid arthritis (RA). Before starting rituximab treatment, patients need to screen for HBV infection by measuring HBsAg and anti-HBc. For patients with RA, GPA, or MPA, perform a complete blood count and platelet count every 2 to 4 months during treatment. Continue to monitor for cytopenias after the last dose until symptoms resolve.